Pembrolizumab, a selective anti-PD-1 humanized monoclonal antibody, reactivates T cells to fight cancer. Immune-related adverse events such as autoimmune colitis, pneumonitis, hepatitis, nephritis, hypophysitis, and thyroiditis may occur during, or weeks to months after therapy. Pemprolizumab-induced synovitis is rarely reported. With the wide use of immunotherapy to treat cancers, physicians need to be aware of this rare immune-related adverse event and provide immediate treatment to avoid permanent joint damage.
AtrashSMakhoulIMizellJSet al.Response of metastatic mucosal melanoma to immunotherapy: it can get worse before it gets better. J Oncol Pharm Pract2017; 23: 215–219.
2.
RobertCRibasAWolchokJDet al.Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet2014; 384: 1109–1117.
3.
TopalianSLHodiFSBrahmerJRet al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med2012; 366: 2443–2454.
4.
ChanMMKeffordRFCarlinoMet al.Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother2015; 38: 37–39.
5.
SalmonJHLambrechtIBrochotPet al.A case of arthritis under pembrolizumab. Joint Bone Spine2017; 84: 243–244.
6.
CappelliLCGutierrezAKBaerANet al.Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis2017; 76: 43–50.
7.
DulosJCarvenGJvan BoxtelSJet al.PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother2012; 35: 169–178.
8.
KornTBettelliEOukkaMet al.IL-17 and Th17 cells. Annu Rev Immunol2009; 27: 485–517.
9.
LeipeJGrunkeMDechantCet al.Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum2010; 62: 2876–2885.
10.
JovanovicDVDi BattistaJAMartel-PelletierJet al.IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages. J Immunol1998; 160: 3513–3521.
11.
FossiezFDjossouOChomaratPet al.T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med1996; 183: 2593–2603.
